Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development.
针对 EBV gp350 和 gp42 的转基因小鼠来源的人类单克隆抗体为治疗开发提供了基础。
期刊:Cell Reports Medicine
影响因子:10.6
doi:10.1016/j.xcrm.2026.102618
Chhan Crystal B, Lang Kevin, Davis Amelia R, Wan Yu-Hsin, Aldridge Nicholas T, Kher Gargi, Scharffenberger Samuel C, Hardy Samantha R, Iureniev Roman, Giltiay Natalia V, Edwards Kristina R, Radtke Stefan, Kiem Hans-Peter, Pancera Marie, McGuire Andrew T